These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21401442)

  • 1. Tolvaptan for the treatment of heart failure: a review of the literature.
    Ambrosy A; Goldsmith SR; Gheorghiade M
    Expert Opin Pharmacother; 2011 Apr; 12(6):961-76. PubMed ID: 21401442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB; Alemayehu A
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
    Ferrer E
    Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
    Pang PS; Gheorghiade M; Dihu J; Swedberg K; Khan S; Maggioni AP; Grinfeld L; Zannad F; Burnett JC; Ouyang J; Udelson JE; Konstam MA
    Am Heart J; 2011 Jun; 161(6):1067-72. PubMed ID: 21641352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
    Cavalcante JL; Khan S; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
    Reilly T; Schork MR
    Ann Pharmacother; 2010 Apr; 44(4):680-7. PubMed ID: 20332337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
    Hori M
    Future Cardiol; 2013 Mar; 9(2):163-76. PubMed ID: 23463968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
    Ferguson-Myrthil N
    Cardiol Rev; 2010; 18(6):313-21. PubMed ID: 20926941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.
    Miyazaki T; Yamamura Y; Onogawa T; Nakamura S; Kinoshita S; Nakayama S; Fujiki H; Mori T
    Endocrinology; 2005 Jul; 146(7):3037-43. PubMed ID: 15831573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
    Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP;
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyponatremia in hospitalized patients: the potential role of tolvaptan.
    Deitelzweig SB; McCormick L
    Hosp Pract (1995); 2011 Aug; 39(3):87-98. PubMed ID: 21881396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.